VISIBLE ALPHA AUTHOR:

About

Rahul is Head of BioPharma Research at Visible Alpha. He has more than 20 years of experience in the biopharmaceutical drug development field encompassing the capital markets, equity research, technology and competitive due diligence, investor outreach, licensing and intellectual property management, business development, and corporate/board leadership. Rahul conducted doctoral and post-doctoral research at Harvard Medical School, in the Department of Hematology and Oncology at Beth Israel Deaconess Medical Center. He received his Ph.D. in Immunology from Tufts University School of Medicine in Boston, M.S. in Microbiology from the University of Montana, Missoula, and B.Sc. in Microbiology from the University of Bombay.

Articles by Rahul:

Visible Alpha GLP 1 Drug Monitor
March 26, 2024

Visible Alpha GLP-1 Drug Monitor: Blockbusters & Up-and-Comers

Madrigal Pharma s Resmetirom Approaching FDA Review for NASH
February 12, 2024

Madrigal Pharma’s Resmetirom Approaching FDA Review for NASH

FDA Approvals A Look Ahead in 2024
January 31, 2024

Potential FDA Approvals: A Look Ahead for 2024

Emerging Drugs Show Promise in Targeting Difficult to Treat Cancers
November 1, 2023

Emerging Drugs Show Promise in Targeting Difficult-to-Treat Cancers

Soaring Revenue Projections for Eli Lilly’s Mounjaro
October 12, 2023

Soaring Revenue Projections for Eli Lilly’s Mounjaro (Diabetes & Obesity)

Eli Lilly Plans to Acquire DICE Therapeutics for $2.4B
June 28, 2023

Eli Lilly Plans to Acquire DICE Therapeutics for $2.4B

Roche’s Vabysmo to Challenge Eylea’s Dominance for Wet AMD
May 25, 2023

Roche’s Vabysmo to Challenge Eylea’s Dominance in Wet AMD Treatment

Analysts Forecast Lofty Revenues for Drugs Treating Type 2 Diabetes and Obesity
May 2, 2023

Analysts Forecast Lofty Revenues for Drugs Treating Type 2 Diabetes and Obesity

New Drugs For Age-related Macular Degeneration To Challenge Market Leaders
March 27, 2023

New Drugs for Age-Related Macular Degeneration to Challenge Market Leaders

Fda Drug Approvals In 2022: Blockbusters In The Making
March 21, 2023

FDA Drug Approvals in 2022: Blockbusters in the Making